A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial Background: The main objective was to study the effect on progression-free survival (PFS) of adding erlotinib to bevacizumab as maintenance treatment following chemotherapy and bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC).
Results: Of the 249 patients enrolled, 80 started maintenance treatment in arm A and 79 in arm B. The rate of any grade 3/4 toxic effect was 53% in arm A and 13% in arm B. Median PFS was 5.7 months in arm A and 4.2 months in arm B (HR = 0.79; 95% confidence interval 0.55-1.12; P = 0.19). Overall survival (OS) from start of induction chemotherapy was 26.7 months in the randomized population, with no difference between the two arms.
Conclusions: The addition of erlotinib to bevacizumab as maintenance treatment after first-line chemotherapy in mCRC did not improve PFS significantly. On-going clinical and translational studies focus on identifying subgroups of patients that may benefit from erlotinib in the maintenance setting.
Clinical Trials number: NCT00598156.
Key words: metastatic colorectal cancer, bevacizumab, erlotinib, maintenance treatment introduction A majority of patients with metastatic colorectal cancer (mCRC) suffer from incurable disease, where the treatment goal is to prolong survival and improve quality of life. Most of these patients receive combination chemotherapy up-front. Addition of bevacizumab, an antibody directed against the vascular endothelial growth factor (VEGF) has been shown to improve outcome [1, 2] .
During palliative chemotherapy, patients develop side-effects that sooner or later will lead to modification or interruption of the treatment. Finding a maintenance treatment that could prolong the progression-free interval without serious sideeffects would be clinically useful. One option is to continue with bevacizumab during the chemotherapy-free period [3] .
Preclinical studies have indicated that dual targeting of both epidermal growth factor receptor (EGFR) and VEGFR pathways may result in supra-additive antitumor effects [4, 5] . In nonsmallcell lung cancer (NSCLC) bevacizumab combined with the EGFR tyrosine kinase inhibitor erlotinib has shown to be an effective maintenance treatment [6] . In mCRC, this maintenance strategy was tested in a phase II trial [7] , with promising results.
The present phase III trial was designed to compare the efficacy and toxic effect of maintenance treatments with bevacizumab + erlotinib and bevacizumab after induction treatment with first-line chemotherapy plus bevacizumab in patients with mCRC.
patients and methods

patient population
Patients ≥18 years of age were eligible for the study if they had mCRC, histologically confirmed adenocarcinoma, not previously treated with chemotherapy for metastatic disease, ECOG performance status 0-1, measurable disease according to RECIST v. 1.0, adequate hematological, renal, and hepatic functions. Prior adjuvant chemotherapy for CRC was allowed if ended >6 months before inclusion.
Patients were excluded in case of major surgery within 28 days before treatment start, CNS metastases, other malignancies within 5 years, serious nonhealing wound or ulcer, bleeding diathesis or coagulopathy, significant ophthalmologic abnormality, uncontrolled hypertension, clinically significant cardiovascular disease within 6 months, or start of anticoagulants for therapeutic purposes within 10 days. This was an investigator sponsored trial. Roche supported the study. A representative from Roche (DB) took part in designing the study protocol but Roche had no role in interpretation of the data.
study design
induction phase
Enrolled patients started induction treatment according to investigator's choice with six cycles of XELOX/XELIRI or nine cycles of FOLFOX/ FOLFIRI in combination with bevacizumab (for chemotherapy schedules see supplementary material, available at Annals of Oncology online). Patients who had at least stable disease after completion of induction treatment were eligible for randomization to one of the maintenance treatments.
maintenance phase
Randomization was carried out in a 1:1 ratio to maintenance treatment with either bevacizumab 7.5 mg/kg every 3 weeks + erlotinib 150 mg daily (arm A) or bevacizumab 7.5 mg/kg as a single agent every 3 weeks (arm B). Stratification was carried out according to best response to induction therapy (complete or partial response, CR/PR, versus stable disease, SD) and to whether an oxaliplatin-containing induction regimen had been used or not.
Maintenance treatment was given until disease progression (PD), intolerable toxic effect, withdrawn consent, planned surgery, noncompliance, serious protocol violation, or lost to follow-up. After withdrawal from the study, further antitumoral therapy was allowed at the investigator's discretion. Survival and additional cancer therapies were documented for all patients every third month until time of death or end of study.
dose modification of study drugs
Bevacizumab was permanently discontinued in case of gastrointestinal perforation, arterial thromboembolic event, symptomatic grade 4 venous thromboembolism, grade 3/4 hemorrhagic event, grade 4 hypertension, or grade 4 proteinuria. Bevacizumab treatment could be temporarily interrupted in the event of lower grade toxic effect or wound healing complication.
Reduction of the erlotinib dose to 100 mg daily was allowed in case of intolerable toxic effect. If toxic effect did not resolve to ≤grade 2 within 2 weeks, a second dose reduction to the minimum dose of 50 mg was carried out. Doses were not re-escalated except in the event of rash resolving to grade ≤2. A dose interruption of more than 3 weeks led to discontinuation of erlotinib and withdrawal from the study.
evaluation of response and toxic effect
Tumor response was evaluated according to the RECIST v.1.0 criteria with a CT scan of thorax and abdomen within 28 days before enrollment, after 8-12 weeks of induction treatment, and before randomization to maintenance treatment. No independent radiology review was done. During the maintenance phase, CT scans were carried out every 9 weeks. Toxic effect was recorded according to NCI-CTCAE version 3.0.
statistical analysis
The primary end point was to assess the effect on progression-free survival (PFS) when adding erlotinib to bevacizumab (arm A) compared with treatment with bevacizumab alone (arm B) in a maintenance setting after chemotherapy and bevacizumab in the first-line treatment of mCRC. The study was designed to detect a difference in PFS between 5 months in arm A and 3 months in arm B. In order to detect this difference at a two-sided significance level of 5% and a power of 90%, 168 randomized patients were needed. With an estimated attrition rate of 30% inclusion of 240 patients was planned. Owing to a higher than expected attrition rate, the statistical analysis plan was amended to investigate the primary end point at a power of 80%, for which 126 events were required.
Toxic effect in the induction phase was studied in the safety analysis population, defined as all patients who had received at least one dose of induction treatment. Response on induction treatment was analyzed in the assessable patients in the intention-to-treat (ITT) population. Toxic effect in the maintenance phase was analyzed in the full analysis set population (FAS), i.e. randomized patients who had received at least one dose of maintenance treatment. PFS and overall survival (OS) from start of maintenance treatment were analyzed in the FAS population.
Comparisons in PFS and OS between treatment arms were made with a two-sided log-rank test, and Kaplan-Meier estimates were calculated. Followup time was calculated as Kaplan-Meier estimated potential follow-up [8] .
results patient characteristics
A total of 249 patients were enrolled in the study. There were no major differences in demographic and baseline disease characteristics of the patients between the two treatment arms (Table 1) . Two patients never started treatment and the safety population consisted of 247 patients (Figure 1 ). Median follow- efficacy and safety induction treatment. Among the 232 patients assessable for response, 48% had PR, 43% SD, and 9% PD. Divided according to chemotherapy regimen, the PR rate was 52% with FOLFOX (n = 50), 44% with XELOX (n = 121), 50% with FOLFIRI (n = 30), and 55% with XELIRI (n = 31). The PR rate on induction treatment of the FAS population was 59% of the patients subsequently randomized to arm A and 54% of patients randomized to arm B. The most common grade 3/4 toxic effects during induction treatment were diarrhea (10%), nausea/vomiting (9%), venous thromboembolic events (8%), infection (6%), fatigue (5%), neuropathy (5%), and hypertension (3%). Forty-five percent of the patients had at least one grade 3/4 toxic effect during induction therapy. Serious gastrointestinal toxic effect, considered at least possibly related to bevacizumab, occurred in original articles Annals of Oncology seven patients during the course of the study. One patient without primary tumor left in situ had a fatal bowel bleeding during induction treatment. Six patients had intestinal perforations of which two occurred in or adjacent to a primary tumor. Five of the perforations occurred during the induction phase and one during maintenance. Three of the six perforations were fatal. maintenance treatment. In the full analysis set population, 159 patients were included (Figure 1) . The primary end point analysis was carried out when 131 events had occured. Median PFS was 5.73 months in arm A and 4.23 months in arm B. This difference was not statistically significant, HR = 0.79; 95% CI 0.55-1.12; P = 0.19 (Figure 2A) .
The median duration of maintenance treatment was 5.5 months in arm A and 5.2 months in arm B. The main reasons for ending maintenance treatment were PD, 68% versus 82% in arms A and B, respectively, and toxic effect in 13% versus 4%.
Four patients in arm A and two in arm B were withdrawn due to planned surgery with a curative intent.
Generally, there were more side-effects in arm A than in arm B, especially skin rash, diarrhea, and anorexia (Table 2) . There were two treatment-related deaths in maintenance phase; one case of liver failure regarded possibly related to erlotinib in arm A and one intestinal perforation in arm B. The frequency of any grade 3/4 toxic effect was 53% in arm A and 13% in arm B. The dose of erlotinib was reduced in 34 (42.5%) patients in arm A. In 24 of these, the daily dose was decreased to 100 mg, whereas 8 and 2 patients had further dose reductions to 50 and 0 mg, respectively.
At the time of analysis, 118 patients of the FAS population had died. Median OS from start of maintenance treatment was 21.5 months in arm A and 22.8 months in arm B, HR 0.88; 95% CI 0.61-1.27; P = 0.51 ( Figure 2B ). The OS from start of induction chemotherapy was 24.7 months in the ITT population (n = 249) and 26.7 months among the 162 randomized patients. poststudy treatment. Most patients (86%) received further anticancer drugs after the termination of maintenance treatment, with no difference between the treatment arms (S1). The proportions of patients that received any type of EGFRinhibiting agent in subsequent lines of therapy were also similar, 25% and 23% in arm A and B, respectively.
discussion
This study does not show a statistically significant gain in PFS when erlotinib is added to bevacizumab as maintenance treatment of mCRC, after first-line chemotherapy combined with bevacizumab, although a numerical increase in median PFS from 4.2 to 5.7 months is noted (HR 0.79, P = 0.19).
In recent years, increasing efforts have been made to identify convenient maintenance strategies that could prolong the time to progression with limited toxic effect and thereby optimizing the quality of life for mCRC patients. One strategy is to use targeted agents, which generally are less toxic than chemotherapy. The efficacy of continuous bevacizumab monotherapy after chemotherapy cessation in mCRC is yet to be determined, but randomized trials are ongoing [9, 10] . The MACRO trial [11] suggested that single bevacizumab be a valid maintenance option.
Addition of erlotinib to bevacizumab resulted in a significantly improved PFS in the maintenance setting for patients with NSCLC [6] . There are still no published data on this maintenance strategy in mCRC, although preliminary results were recently presented from the GERCOR DREAM trial with a study design very similar to ours [12] . In their study population of 700 mCRC patients, a statistically significant improvement in PFS was found with the addition of erlotinib to bevacizumab as maintenance treatment after first-line chemotherapy plus bevacizumab (HR 0.73; 95% CI 0.59-0.91; P = 0.005). The median PFS on maintenance treatment increased from 4.6 to 5.8 months, i.e. similar to the present study (4.2 versus 5.7 months). The reason for lack of significance in our study could be the lower sample size. 
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The median OS in the present study was 24.7 months in the ITT population and 26.7 months among randomized patients, which compares favorably to other recent first-line chemotherapy studies including biologicals in mCRC, with OS typically ranging from 18 to 24 months [1, [13] [14] [15] . Previous studies have suggested that prolonged bevacizumab exposure beyond first-line chemotherapy may have a positive impact on survival [16, 17] . Whether the long OS in our study was due to the treatment or to a positive patient selection cannot be determined.
A general purpose with maintenance therapy is the prospect of offering a prolonged tumor control with limited toxic effect. In the present study, there was clearly more toxic effect with the addition of erlotinib to bevacizumab (Table 2) . This was mainly due to a higher frequency of fatigue, diarrhea, rash, and other skin/nail disorders. Most of them are well-known erlotinibrelated side-effects that are usually easily managed, and the proportions of patients that stopped maintenance treatment due to side-effects were limited, 13% and 4% in arm A and B, respectively. Serious gastrointestinal toxic effect, at least possibly related to bevacizumab, occurred in seven patients. Six of these had GI-perforations (2%), which is well in line with previous studies [1, 12, 15, 17] .
For the EGFR-inhibiting antibodies cetuximab and panitumumab, which have an established role in the management of mCRC, the effect is mainly seen in KRAS wild-type (wt) tumors [14] . Whether this is true also for erlotinib is not known. We have recently finished recruitment of 232 patients in a follow-up study, ACT2 [18] , in which patients with KRAS wt tumors are randomized to bevacizumab ± erlotinib and patients with KRAS-mutated tumors to bevacizumab or metronomic capecitabine as maintenance treatment. The outcome of the two ACT studies, along with ongoing translational studies focusing mainly on proteins and genes involved in the EGFR and VEGF cascades, will hopefully help us identify 
